Taysha Gene Therapies, Inc. (TSHA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 3 | 15 | 8 | 10 | 5 | 2 |
| Operating profit | $m | -110 | -153 | ||||||
| Net profit | $m | -43 | -175 | -166 | -112 | -89 | -109 | -150 | -176 |
| EPS reported | $ | -0.34 | -0.42 | ||||||
| Operating cashflow per share | $ | -0.29 | -0.31 | ||||||
| Capex per share | $ | 0.00 | 0.01 | ||||||
| FCF per share | $ | -0.29 | -0.31 | ||||||
| Free cash flow | $m | -94 | -136 | ||||||
| Net debt | $m | -302 | -406 | ||||||
| Book value equity | $m | 247 | 387 | ||||||
| Book value per share | $ | 0.77 | 1.05 | ||||||
| Number of shares | m | 319.71 | 369.04 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 7.12 | 4.54 | ||||||
| P/S LTM | x | 179.93 | 320.59 | ||||||
| P/FCF LTM | x | -18.74 | -12.97 | ||||||
| EV/EBITDA LTM | x | -13.52 | -9.79 | ||||||
| EV/Sales LTM | x | 149.07 | 241.82 | ||||||
| Earnings Yield LTM | % | -6.20% | -5.49% | ||||||
| FCF Yield | % | -5.34% | -7.71% | ||||||
| Quality | |||||||||
| ROE | % | -44.14% | -56.07% | ||||||
| ROIC | % | -34.88% | -47.30% | ||||||
| Operating margin | % | -11.31% | -17.74% | ||||||
| Gross margin | % | +100.00% | +88.22% | ||||||
| FCF/Sales | % | -960.07% | -1543.7% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +17.28% | -34.18% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -5.16 | -2.44 | ||||||
| Net Debt/EBITDA | x | 2.80 | 2.00 | ||||||
| EBIT/Net interest | x | -1,753.94 | -2,501.19 | ||||||
| Net debt/market cap | % | +1.03% | +0.86% | ||||||
| Net debt/Equity | x | -1.22 | -1.05 | ||||||
| Gross debt/equity | x | 0.07 | 0.14 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Taysha Gene Therapies, Inc. (TSHA)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free